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Abstract Recent studies suggest that allergic rhinitis is
highly prevalent in the elderly population, but is under-
diagnosed and undertreated. This review article briefly
introduces allergic rhinitis in the elderly (epidemiology and
pathophysiology) and identifies the main goals of treatment
in these patients with respect to age-related physiological
factors, comorbid conditions and polypharmacy. The pri-
mary focus of the article is a narrative review of the lit-
erature concerning the different types of treatment options
in elderly patients aged 60? years (pharmacological ther-
apy and allergen-specific immunotherapy). The main
management trend for allergic rhinitis in elderly patients is
the same as the trend in young patients. Second-generation
antihistamines and nasal glucocorticosteroids are also the
first-line therapies in seniors. In a few trials, allergen-
specific immunotherapy for grass pollen or house dust
mites has been shown to be effective and safe in patients
aged 60 years or older with allergic rhinitis. In conclusion,
undertreatment of allergic rhinitis in the elderly is a reality.
Pharmacological treatment is quite similar in both older
and younger patients with allergic rhinitis.
Key Points
Allergic rhinitis is undertreated in elderly patients.
Antihistamines and nasal glucocorticosteroids are
the first-line therapies in patients over 60 years of
age.
Attention should be paid to the use of oral
antihistamines in patients with comorbidities and
polymedication.
1 Introduction
Allergic rhinitis is a significant problem worldwide. The
prevalence of rhinitis in the USA is estimated to be
between 10 and 30% in adults [1, 2]. According to Allergic
Rhinitis and its Impact on Asthma (ARIA), the prevalence
of allergic rhinitis in the population in general in Europe
and the USA is between 40 and 50% [1]. Unfortunately, the
ARIA guidelines are not focused on seniors and do not
evaluate differences in the diagnosis and treatment of
rhinitis. ARIA and the Joint Task Force highlight the
problem of rhinitis in the elderly, but do not link rhinitis to
allergies [1, 3]. No data are available concerning how
allergic rhinitis affects the quality of life of elderly patients
and how to determine the needs of elderly people with
allergic rhinitis [2, 3].
The increasing number of patients with allergies and the
aging world population are causing an increase in allergic
diseases in patients over 60 years of age [4, 5]. Although
many authors have analyzed the epidemiology, diagnosis
and treatment of allergies, the occurrence and natural
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course of allergic disease in elderly patients have been
somewhat neglected. The prevalence of allergic rhinitis in
elderly patients is approximately 5–8% and decreases with
age [6–8], although some national epidemiological data
suggest that the number of patients with allergic diseases
may be greater than 10% [9, 10]. However, the available
epidemiological data are rudimentary, and international
cohort studies based on a large elderly population are
lacking. Therefore, allergic rhinitis in elderly people
remains poorly perceived [10–13].
Few studies have analyzed groups of patients over
60 years of age. Some studies have analyzed the epi-
demiological situation of rhinitis in adults or elderly people
without considering allergic mechanisms.
Various types of chronic rhinitis that sometimes impede a
proper diagnosis are noticeable in elderly people [4, 11]. In
addition to allergic rhinitis, non-allergic types of rhinitis
include vasomotoric rhinitis, atrophic rhinitis, drug-induced
rhinitis and non-allergic rhinitis with eosinophilia [11].
The aim of this article is to review the present literature
on allergic rhinitis in the elderly and to discuss the
approach to treatment in these patients, including phar-
macotherapy and allergen-specific immunotherapy. A cut-
off age of 60 years was used as this returned the largest
number of studies that discussed allergic rhinitis in the
elderly. However, the age limit that defines ‘‘elderly’’ is
variable and a trend toward a change to 65, 70 years or
even higher has been observed.
2 Aging of the Nose and Immune System
2.1 Aging of the Nose
Nasal anatomical and physiological changes during aging
significantly influence rhinitis symptoms. Aging causes an
increase in cholinergic activity and mucosal atrophy,
decreased mucosal elasticity, weakened mucociliary func-
tions and weakening of the septal cartilage [2, 14]. The
nasal mucosa becomes dry and nasal congestion is frequent
[14, 15]. Nasal congestion leads to irritation and damage of
the mucosa and causes epistaxis [8]. Toppozada suggested
that the nasal mucosa was normal, although the basement
membrane became thicker and structural atrophy was
present, in postmenopausal subjects [16]. However, other
studies did not confirm these changes [17].
2.2 Immunosenescence
The aging immune system causes many changes, including
a decreased non-specific immune response with a decline
in the activity of phagocytes and cytotoxic cells. Signifi-
cant changes have been observed in T lymphocyte profiles
during aging, including a shift toward CD4? T memory
cells and a reduction in naive T lymphocytes [8, 18].
Additionally, a decrease occurs in the proliferative T
lymphocyte response and the cytokine production profile
shifts from Th1 to Th2. A decrease in the number and
activity of B lymphocytes and the presence of higher
concentrations of autoantibodies in the serum are typical of
the humoral immune response in elderly patients [18, 19].
This ‘‘immunosenescence’’ is a result of natural genetic
aging, environmental factors and lifestyle [8, 9]. However,
these changes do not appear to significantly limit the
prevalence of allergic diseases in elderly patients [8]. The
onset of immunosenescence is very individual, but is
observed in all patients over 75 years of age. However, this
phenomenon is often not noticeable in individuals between
60 and 75 years of age with no other health burdens [20].
3 Pathophysiology of Allergic Rhinitis in Seniors
Allergic rhinitis is generally caused by immunoglobulin E
(IgE)-mediated allergic inflammation in the nasal mucosa
[1, 21]. The acute phase of the allergic reaction develops
within minutes of allergen exposure and is primarily caused
by histamine and arachidonic acid metabolites (leukotrienes,
prostaglandins, and thromboxanes) [1, 20]. The late-phase
allergic reaction, which occurs within 6–12 h of allergen
exposure, is characterized by an influx of monocytes, T
lymphocytes, basophils, and eosinophils to the nasal mucosa
[1, 21, 22]. In elderly patients, this phase may be not noticed
by patients due to the very limited or non-existent course
[11]. The intermittent nasal symptoms induced by an allergy
to pollens or molds might also generate intensive symptoms
in elderly patients, although a significant reduction may
occur in patients over 75 years of age. The persistent allergic
rhinitis symptoms induced by house dust mites, pet dander,
and cockroach allergens are frequently indistinguishable
from non-allergic rhinitis symptoms in seniors. However,
the total and specific IgE levels are increased in the serum,
and positive skin prick tests to common inhalant allergens
occur in the majority of these patients [2]. In a small sub-
group of elderly patients, only local nasal allergic reactions
occur without a positive allergy diagnosis. This local allergic
rhinitis is diagnosed on the basis of positive nasal provo-
cation tests and typical allergic symptoms [23]. This disease
is difficult to identify, particularly in elderly people [24].
The classification of allergic rhinitis according to ARIA
is also helpful for seniors [1].
In elderly patients, allergic rhinitis can coexist with non-
allergic rhinitis [25, 26]. Allergy skin testing and/or IgE
measurement are used to distinguish between allergic and
non-allergic rhinitis [2]. However, these methods have
been criticized by some authors [27]. Non-allergic rhinitis
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generally has a milder course, with fewer symptoms of
sneezing, nasal pruritus and conjunctivitis and a worse
clinical effect after antihistamine drug intake [2]. This type
of rhinitis is predominant in patients over 75 years of age.
The proportions of allergic rhinitis and non-allergic rhinitis
are the same as the proportions reported in younger patients
[2, 8].
4 The Diagnosis of Allergic Rhinitis in the Elderly
The diagnosis of rhinitis in elderly patients is difficult and
requires patience. Elderly people are not a homogenous
group [21, 22] and include younger patients in their sixties
and older patients in their late seventies or eighties. The
younger group has more in common with younger patients
and shares the nasal mucosa pathophysiology, a ‘‘better
profile’’ of health and a better ability to tolerate drugs that
affect the metabolism. Older seniors are a completely dif-
ferent group. This group has numerous comorbidities that
must be treated, such as arterial hypertension, brain dis-
orders, and arteriosclerosis. After age 75, patients are fre-
quently polymedicated, which often influences the
diagnosis and treatment of allergic rhinitis [22]. For
example, acetylcholinesterase inhibitors, which are com-
monly used in elderly patients with cognitive impairment,
increase anterior rhinorrhea [1].
Many doctors believe that the diagnosis of allergies in
patients over 60 years old is impossible [28, 29]. Elderly
patients and their doctors focus on diseases that more typi-
cally affect patients over 60 years of age, such as diabetes,
ischemic disease, and arterial hypertension, and minimize
the problem of allergic rhinitis. Unfortunately, these atti-
tudes frequently lead to a reduced quality of life [28, 30].
Confirmation of an allergic rhinitis diagnosis requires a
detailed medical history, clinical otolaryngological (HNO)
examination and diagnostic allergy procedures [3, 21].
The guidelines differentiate the following identical symp-
toms of allergic nasal reactions: watery anterior rhinorrhea,
paroxysmal sneezing, nasal obstructions, nasal pruritus and
the coexistence of conjunctivitis. The presence of a minimum
of two of these symptoms suggests allergic rhinitis.
An allergy diagnosis based on the typical procedure of a
skin prick test to identify common allergens and the
determination of the total serum and specific IgE concen-
trations should be conducted in older patients [9]. Nasal
provocation tests with inhalant allergens and the use of
acoustic rhinometry or anterior rhinomanometry are
sometimes helpful [24]. Notably, the diagnostic value of
the skin prick test and the serum IgE concentration could
be decreased in the elderly due to aging of the skin and
immune system [9]. Mediaty et al. observed total serum
IgE reductions with age in patients with allergic diseases,
but not in elderly patients with atopic dermatitis and an IgE
concentration of [300 kU/L [31]. However, opposing
opinions suggest that diagnostic procedures for allergies
are possible and valuable because the differences between
younger and older patients in skin reactivity and IgE con-
centrations are not evident [9, 23]. Huss et al. confirmed a
positive skin prick test in approximately three-fourths of 75
elderly patients who were allergic to common inhalant
allergens [32]. Despite this limitation, King et al. recom-
mended this type of diagnosis in the elderly as a valuable
tool when doctors avoided applying the tests to areas of the
skin affected by atrophic changes of the photoaging type
[33]. In some studies, authors observed a high concentra-
tion of total and specific IgE to inhalants and rare food
allergens in patients over 60 years of age [9].
An additional diagnostic procedure that allows moni-
toring of inflammation in the upper airways is the mea-
surement of nitric oxide [34]. Nasal nitric oxide is a good
marker of inflammatory diseases of the upper airways, such
as allergic rhinitis, particularly when monitoring thera-
peutic effectiveness. This method is also used in elderly
patients [35].
5 The Treatment of Allergic Rhinitis in Elderly
Patients
No specific therapies exist for allergic rhinitis in the
elderly. Treatments include pharmacological treatment,
attempts at allergen-specific immunotherapy and a reduc-
tion or elimination of allergens from the patients’ envi-
ronments. According to the guidelines, pharmacological
treatment includes topical and oral drugs [1, 3]. The type of
drug used should be related to the clinical rhinitis symp-
toms [1, 21]. Intranasal glucocorticosteroids and intranasal
and/or oral antihistamine drugs are the first-line therapies
[1, 3]. The main problem with these therapies in the elderly
is interactions between drugs or between drugs and dis-
eases, especially in patients over 75 years of age. The risk
of adverse events increases exponentially with the number
of drugs used in older people [36]. Additionally, this risk is
higher in seniors with concomitant liver or renal impair-
ment [37]. Few studies have analyzed drug–drug interac-
tions in general in elderly people, and most of the findings
have suggested that drug metabolism is individual and not
dependent on age. Accumulation of a drug that inhibits
metabolism can also lead to the intensification of adverse
events. One of the most important problems is interactions
with anticholinergic drugs. Many drugs have antimus-
carinic actions, and combining them in therapy can induce
many serious adverse reactions, such as delirium episodes
and urinary retention [36]. Unfortunately, there are no
detailed data about drugs used for allergic rhinitis.
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5.1 Glucocorticosteroids
Glucocorticosteroids are used in upper airway diseases
including allergic and non-allergic rhinitis, particularly non-
allergic rhinitis with eosinophilia syndrome (NARES), acute
and chronic rhinosinusitis with and without nasal polyps,
and adenoid hypertrophy with or without middle ear disease
[37]. This evidence suggests that intranasal corticosteroids
produce greater nasal symptom relief than topical antihis-
tamines (H1 receptor antagonists) even if no difference in
ocular symptoms has been reported [38, 39]. Corticosteroid
nasal sprays include beclomethasone dipropionate, budes-
onide, ciclesonide, flunisolide, fluticasone furoate, fluticas-
one propionate, triamcinolone acetonide, and mometasone
furoate. The design of topically active steroid formulations
has provided a much better therapeutic ratio than oral cor-
ticosteroids. The pharmacodynamic and pharmacokinetic
properties of these agents play important roles in facilitating
local anti-inflammatory activity with a low rate of side
effects [40, 41]. No data suggest increased side effects after
the use of these drugs in older patients [36].
Many studies have confirmed that intranasal steroids are
most beneficial in allergic rhinitis in general, due to their anti-
inflammatory activities [1, 41]. Steroids are also the recom-
mended front-line treatment in every type of allergic rhinitis
(intermittent or perennial) regardless of the severity in patients
over 60 years of age [3, 41]. However, few studies have
investigated the prolonged use of nasal steroids in elderly
people. These drugs are well tolerated by the elderly, with
adverse reactions identical to those described in the younger
population, such as epistaxis, dryness and a burning sensation
in the nose [11]. The prolonged use of these drugs frequently
unblocks the nose and improves olfaction. No data are avail-
able regarding the role of chronically administered nasal ster-
oids in osteoporosis and diabetes in elderly people; however,
these patients should be monitored. Mometasone and cicleso-
nide have minimal bioavailability and therefore are the safest
options; this effect is particularly important in the elderly [33].
Oral glucocorticosteroids are not recommended for the
treatment of allergic rhinitis in older patients [21]. Some
guidelines permit their use in some cases of severe allergic
rhinitis; however, adverse events must be expected because
these events are typical with systemic steroid use and may
negate the benefits [1]. Adverse events, including osteo-
porosis, diabetes, and arterial hypertension, after systemic
steroid use are very individual but frequent and may not
depend on age [42]. Each patient must be individually
analyzed for comorbidities.
5.2 Antihistamines
Antihistamines are a standard therapy for most types of
allergic rhinitis, conjunctivitis and other allergic skin
diseases in elderly patients [21]. Most H1 antihistamines
have good absorption when administered orally, and the
majority of H1 antihistamines reach effective plasma con-
centration within 3 h after administration.
Based on our present knowledge, first-generation anti-
histamines are not recommended for the treatment of
allergic rhinitis, especially in older patients, because there
is a high risk of adverse reactions in elderly people due to
the lack of receptor specificity as well as these drugs being
able to cross the blood–brain barrier [43]. Anxiety, con-
fusion, dyskinesis, sedation or sleepiness are common in
older patients, as are arrhythmias, urinary disturbances,
constipation, hypotension, memory dysfunction, and
problems with kinetic coordination that lead to falls
[44, 45]. Additionally, first-generation antihistamines fre-
quently interact with other medications [44].
Second-generation antihistamines are effective in
elderly patients with allergic rhinitis in drops and oral
forms. Their safety is based on a relatively low rate of
passage across the blood–brain barrier. Simons observed
that the new H1-receptor antagonists cetirizine and lor-
atadine were less likely to cause adverse central nervous
system effects than the old H1-antagonists in the elderly
[48]. However, no sufficient and precise data showing that
these drugs are safe for the elderly are available.
Fexofenadine, cetirizine, loratadine, levocetirizine,
desloratadine, bilastine and ebastine are most commonly
used in elderly people [21]. These drugs have a high
affinity for the H1 receptor and no or weak antagonist
activity against the anticholinergic and alfa-adreno recep-
tors [36, 44]. The use of bilastine should be emphasized
because it has been proven to have no effect on the
cholinergic receptor, which is of great importance for safe
application in elderly people [45]. Unfortunately, deslo-
ratadine and loratadine have important interactions with the
cholinergic receptors and thus are not indicated for patients
with symptoms such as dry eye syndrome [46, 47].
Some studies have established the anti-inflammatory
effects of second-generation antihistamine drugs. Addi-
tionally, their interactions with other drugs are relatively
slight [48]. However, the majority of second-generation
antihistamines are metabolized by the cytochrome 450
enzyme during their first pass through the liver and thus are
not recommended for patients with significant liver dys-
function [48]. Furthermore, for drugs with systemic
absorption, impairment of renal or hepatic function may be
important. For example, cetirizine is excreted by the kid-
ney, and in patients with renal insufficiency it must be used
with caution. No mention is made of this issue, and this is
of particular importance because renal insufficiency is
frequent in the elderly, even in those with normal serum
creatinine. Therefore, patients with renal impairment
should take lower daily doses of antihistamines such as
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azelastine, ebastine, desloratadine and cetirizine [49, 50].
Apart from terfenadine, the remaining drugs in this group
are cardiologically safe. However, parallel use of second-
generation antihistamines (particularly ebastine) with drugs
(i.e., ketoconazole, macrolides, quinolones, and cime-
tidine) that inhibit microsomal enzymes of the liver could
stimulate arrhythmias in older patients [51].
Topically applicable antihistamines, such as nasal
sprays or eye drops, do not induce systemic adverse reac-
tions or drug interactions [50–52].
Doctors should choose antihistamines for elderly patients
through careful consideration of the risk of adverse events
based on laboratory renal and liver function tests. The
reduction of the daily dose of oral antihistamine should be
especially considered in patients over 75 years of age [49, 51].
5.3 Decongestants
This group of topical or systemic drugs affects nasal
blockage, which is a significant problem in affected
patients. Therefore, these drugs are unfortunately over used
and should not be a first-line therapy or used as a
monotherapy, particularly for a prolonged period [1, 21].
Notably, these drugs may generate many adverse events,
such as increased arterial hypertension, headache, arousal,
prostatism, and aggravation of glaucoma, and urination,
which are particularly burdensome in the elderly [21].
5.4 Antileukotrienes
Cysteinyl leukotrienes (CysLTs) are key elements in
allergic inflammation. Thus, the antagonism of CysLTs
appears to be a potential target for allergic rhinitis man-
agement. The combination of antileukotrienes and anti-
histamines showed a synergistic effect for the treatment of
seasonal allergic rhinitis. This combination acts quickly on
all nasal symptoms and is well tolerated in older patients
[51].
5.5 Intranasal Anticholinergics
This treatment is occasionally used in elderly patients with
allergic rhinitis and persistent rhinorrhea, with good tol-
erance and no adverse systemic events, but is more fre-
quently used in non-allergic rhinitis [21, 53].
5.6 Other Treatment Approaches
Occasionally, nasal irrigation with isotonic sodium chlo-
ride is recommended in situations in which nasal dryness
coexists with allergic rhinitis. Irrigation is also beneficial
for removing the nasal mucosa [11], which is important in
patients with an aging nose and dryness.
Combinations of the previously mentioned drugs are
recommended when monotherapy is ineffective. This
therapeutic step is the same as described in young patients.
The most common drug combination is nasal steroids and
nasal or oral antihistamines or a short period of use of nasal
decongestants with concomitant use of nasal steroids and/
or nasal antihistamines [1, 3].
5.7 Allergen-Specific Immunotherapy
Allergen-specific subcutaneous immunotherapy is a safe and
effective treatment method, particularly for allergic rhinitis
in the general population. Several studies have confirmed
this therapy’s efficacy in several randomized controlled
immunotherapy trials, with a high degree of safety and
efficacy. However, although doubts regarding the efficacy of
immunotherapy in adults and children remain, no broad data
exist for elderly patients. Despite the lack of objective
contraindications, specific immunotherapy has not played a
significant role in treating elderly patients, possibly because
of the lack of evidence of safety in this group. This treatment
should be considered only in patients with clinical nasal
symptoms associated with a confirmation of an IgE-medi-
ated reaction to a specific inhalant allergen. However,
unstable circulatory, neoplasm and autoimmune diseases
could be very important contraindications and should be
very carefully checked in elderly patients [54–56]. Further-
more, immunotherapy should be administered with caution
to patients (especially in seniors) receiving beta-blockers or
angiotensin-converting enzyme inhibitors because of the
higher risk of anaphylactic shock [56].
Recently, some evidence has indicated that allergen-
specific immunotherapy is safe and effective in patients over
60 years of age [57]. A double-blind, placebo-controlled trial
with sublingual, allergen-specific immunotherapy to Der-
matophagoides pteronyssinus andDermatophagoides farinae
in patients over 60 years of age confirmed its efficacy and
safety during 3 years of therapy [58]. A total of 51 subjects in
the sublingual allergen-specific immunotherapy group and 57
in the placebo group were monitored for 3 years. The total
nasal symptom score decreased by 44% in the active group
and 6% in the placebo group at the end of the 3 years of
therapy. The totalmedication score decreased significantly by
a maximum of 51% in the active group and decreased sig-
nificantly in the placebo control group. No adverse systemic
reactions were reported during the study. These results were
confirmed by a similar study with grass pollen [59].
Despite sublingual immunotherapy, Asero assessed the
efficacy of injection immunotherapy for birch and ragweed
allergies in patients over 54 years of age [60]. However,
this trial was not placebo-controlled [60]. In 2016, the first
study with injections for allergen immunotherapy to grass
pollen with a double-blind, placebo-controlled protocol
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was conducted. Sixty-two 60- to 75-year-old patients with
seasonal allergic rhinitis and a confirmed grass pollen
allergy according to a skin prick test, nasal provocation and
measurement of serum IgE were included in the study. The
patients were individually randomized to the active or
placebo groups using a double-blind method. A total of 33
subjects in the subcutaneous immunotherapy (SCIT) group
and 29 subjects in the placebo group were monitored for
3 years. The total nasal symptom score decreased by 76%
in the active group and 5% in the placebo group after
3 years of SCIT. At the end of therapy, the total medication
score of the active group decreased significantly by a
maximum of 62%. No adverse systemic reactions were
reported during therapy [61].
More trials are necessary to determine the degree of
effectiveness and safety of immunotherapy in elderly
patients. A greater application of immunotherapy in elderly
people may allow a reduction in chronic drug treatment,
which can lead to polytherapy, typical in the elderly.
However, any prolonged therapy can lead to decreased
adherence in elderly people. Moreover, some prolonged
therapies may not be acceptable to elderly patients. The
following factors influence the degree of adherence in
elderly people: mental impairment, decreased vision,
problems with swallowing and motor deficiencies [62].
In these cases, doctors should monitor therapy, using
recommended tools, such as questionnaires or assessment
of the number of used drug packages [62].
5.8 Allergen Avoidance
Reducing allergen exposure has significantly influenced
allergic nasal improvements. Numerous studies have con-
firmed this influence, particularly in young patients with an
allergy to house dust mites [1, 11]. However, Huss et al.
demonstrated that high levels of common home allergens,
such as dust mites, cockroaches, cats and dogs, could sig-
nificantly influence allergic asthma and rhinitis in patients
over 80 years of age [32].
6 Conclusions
Allergic rhinitis occurs more often than is commonly
believed in older people. Aging of the immune system does
not reduce the frequency of allergic rhinitis. The diagnosis
of allergic disease is similar to the diagnosis in young
patients. A great deal of evidence indicates that the man-
agement of allergic rhinitis in the elderly should be the
same as the management in younger patients. However, all
recommended therapies should be administered with cau-
tion to seniors with other chronic diseases, polymedication
and organ dysfunctions. Cooperation between doctors and
senior patients and their families or caregivers in the
diagnosis and treatment of any allergic disease is also
extremely important.
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